- Home
- Companies
- CIS Pharma AG
- Products
- Mobile Shelving for Light and ...
CIS Pharma - Nanobody-Radionuclide Conjugate
Due to its fast and deadly nature, brain cancer glioblastoma, GBM, comprises a poor prognosis. Treatment options are limited, and recurrence is universal. The blood-brain barrier, BBB, excludes the vast majority of cancer therapeutics from the brain. Clinical evidence demonstrates that there is a clinically significant tumor burden with an intact BBB in all GBM.
A novel target was found to play an important role in GBM. CIS Pharma develops a nanobody to target the respective surface protein. Nanobodies are smaller in size, 10% of a full antibody, and allow deeper penetration of solid tumors with faster accumulation in the target tissue.
The target plays a role in the adaptive immune system and is a potential checkpoint inhibitor ligand. It is overexpressed in differentiated malignant cells and promotes migration, invasion, angiogenesis and chemoresistance of tumor cells.
Based on CIS Pharma’s payload technology, the nanobody is designed to carry one or more different types of diagnostic or therapeutic radionuclides that are conjugated to a single nanobody.